Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
暂无分享,去创建一个
S H Kim | L Meijer | L. Meijer | Sung-Hou Kim | S. Kim | M. Strnad | L. Havlícek | W. F. De Azevedo | S. Leclerc | W. F. Azevedo | W F De Azevedo | S Leclerc | L Havlicek | M Strnad | S. Leclerc
[1] X. Graña,et al. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). , 1995, Oncogene.
[2] L Meijer,et al. Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine , 1995, Proteins.
[3] R. A. Swank,et al. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. , 1992, Biochemical and biophysical research communications.
[4] P. Russell,et al. Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. , 1990, Genes & development.
[5] A. Harris,et al. Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. , 1995, Journal of cell science.
[6] P. Guerrier,et al. 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. , 1988, Experimental cell research.
[7] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[8] A T Brünger,et al. Slow-cooling protocols for crystallographic refinement by simulated annealing. , 1990, Acta crystallographica. Section A, Foundations of crystallography.
[9] E. Sausville,et al. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. , 1993, Biochemical pharmacology.
[10] Sung-Hou Kim,et al. Sparse matrix sampling: a screening method for crystallization of proteins , 1991 .
[11] A. Murray,et al. The Cell Cycle: An Introduction , 1993 .
[12] L Meijer,et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.
[13] S H Kim,et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[14] L. Meijer,et al. Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. , 1988, Experimental cell research.
[15] N. Saijo,et al. Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action. , 1994, Biochemical and biophysical research communications.
[16] S. Kim,et al. Purification and crystallization of human cyclin-dependent kinase 2. , 1993, Journal of molecular biology.
[17] Jean,et al. Cyclin B targets p34cdc2 for tyrosine phosphorylation. , 1991, The EMBO journal.
[18] E. Nabel,et al. The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo , 1995, Nature Medicine.
[19] L. Meijer,et al. Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions , 1994, FEBS letters.
[20] C. Cordon-Cardo. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.
[21] J. L. Smith,et al. Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution. , 1987, Journal of molecular biology.
[22] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[23] L. Rebhun,et al. Cleavage inhibition in marine eggs by puromycin and 6-dimethylaminopurine. , 1973, Experimental cell research.
[24] C. Chothia,et al. The structure of protein-protein recognition sites. , 1990, The Journal of biological chemistry.
[25] C. W. Parker,et al. Inhibitors of two enzymes which metabolize cytokinins , 1986 .
[26] Sung-Hou Kim,et al. Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.
[27] E. Schierenberg,et al. Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases , 1995, Biology of the cell.
[28] V. Rialet,et al. A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. , 1991, Anticancer research.
[29] S. Broder,et al. Molecular foundations of cancer: New targets for intervention , 1995, Nature Medicine.
[30] L. Meijer,et al. A starfish oocyte user's guide , 1984 .
[31] I. Wilson,et al. Antibody-antigen interactions , 1993 .
[32] E. Sausville,et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.
[33] E. Sausville,et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.
[34] M. L. Connolly. Analytical molecular surface calculation , 1983 .
[35] M. Kitagawa,et al. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. , 1993, Oncogene.
[36] L. Meijer,et al. Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. , 1992, Anticancer research.
[37] S. Elledge,et al. A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. , 1996, Trends in cell biology.
[38] J. Thornton,et al. Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.
[39] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[40] J. H. Wang,et al. Purification of a 15-kDa cdk4- and cdk5-binding protein. , 1994, The Journal of biological chemistry.
[41] J. Blow,et al. Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.
[42] A. Okuyama,et al. Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. , 1994, Biochemical and biophysical research communications.
[43] M. Kitagawa,et al. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. , 1994, Oncogene.
[44] J. Pines,et al. Cyclins and cyclin-dependent kinases: a biochemical view. , 1995, The Biochemical journal.
[45] David O. Morgan,et al. Principles of CDK regulation , 1995, Nature.
[46] L. Meijer. Chemical inhibitors of cyclin-dependent kinases. , 1996, Trends in cell biology.
[47] H. Tung,et al. Progress in Cell Cycle Research , 1999, Progress in Cell Cycle Research.
[48] F. Chang. The cell cycle: A practical approach , 1995 .
[49] H. Tung,et al. Interaction between the cell-cycle-control proteins p34cdc2 and p9CKShs2. Evidence for two cooperative binding domains in p9CKShs2. , 1992, European journal of biochemistry.